Savella

Quick links to important sections

Savella

Method of action: Psychoanaleptics

Treatment option: Fibromyalgia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Savella

Quick Facts

Property Description
Active ingredient Milnacipran hydrochloride
Form Oral tablet, film-coated
Pharmacological class Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
General purpose Systemic modulation of pain signaling
Origin Synthetic chemical compound
Prescription Status Prescription Only (Rx)

Savella is a prescription pharmaceutical product used in adults to systemically influence the body’s pain signaling pathways. The medicine is a synthetic, single-active-ingredient agent defined by its focused, dual effects on two key neurotransmitters in the central nervous system. Its development and approval were supported by clinical studies specifically analyzing patient response to dual reuptake inhibition.


What Type of Medicine is Savella?

Savella is formally classified as a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), a distinct pharmacological drug class. The medication's active chemical component is milnacipran hydrochloride, and the product is manufactured in the form of an oral tablet.

Milnacipran is a uniquely differentiated compound within the SNRI class. Pharmacological studies have clinically recognized its profile for having the most balanced potency ratio for the reuptake inhibition of both serotonin and norepinephrine when compared with other, similar SNRI agents. This unique, balanced action is supported by research detailing its focused mechanism. This confirms the medicine is specifically engineered to target both key chemical messengers simultaneously across its therapeutic range, unlike some other agents that may prioritize one over the other.


Composition, Form, and General Purpose

The foundational composition of Savella involves the active substance, milnacipran hydrochloride, presented within an oral tablet designed for reliable systemic delivery into the bloodstream. As a synthetic compound, it ensures standardized purity for its systemic action.

The general purpose of this pharmaceutical agent is to modulate the signaling processes associated with chronic discomfort. Milnacipran achieves this by inhibiting the reabsorption (reuptake) of the two key neurotransmitters, serotonin and norepinephrine, back into nerve cells. By increasing the functional availability of both messengers in the spaces between neurons, the drug influences neurochemical balances that regulate the perception and severity of pain signals, contributing to the management of long-term conditions. The assessment indicates that the drug’s effectiveness was evaluated based on systemic improvement across several aspects of a chronic condition, rather than localized relief.

Regulatory References

  1. DailyMed Label for Savella (milnacipran hydrochloride)

What side effects are possible with Savella?

Adverse Reaction Scope

Category Description
Key adverse reaction categories Gastrointestinal, Cardiovascular, Nervous System, Psychiatric, and Skin disorders.
Frequency classification (very common / common) Very Common: Nausea, Headache, Dry Mouth, Constipation, Hot flush. Common: Vomiting, Dizziness, Anxiety, Insomnia, Hypertension, Tachycardia, Palpitations, Hyperhidrosis (sweating), Tremor, Urinary hesitation, Erectile dysfunction.
System-organ classes involved Gastrointestinal Disorders, Cardiac Disorders, Vascular Disorders, Nervous System Disorders, Psychiatric Disorders, Skin and Subcutaneous Tissue Disorders, Renal and Urinary Disorders, Reproductive System Disorders.
Serious adverse reactions (as documented in regulatory sources) Serotonin Syndrome, Suicidal Thoughts and Behaviors (especially in young adults), Severe Cutaneous Adverse Reactions, Hepatotoxicity (severe liver injury), and sustained Elevated Blood Pressure and Heart Rate.
Population-specific safety considerations Not recommended in individuals with severe renal impairment or severe hepatic impairment. Third-trimester use during pregnancy is associated with a risk of Persistent Pulmonary Hypertension of the Newborn.
Dose- or exposure-related patterns (if explicitly stated) Nausea is officially documented as being more frequent at treatment initiation. Cardiovascular effects are noted as potential safety concerns during dose escalation.
Safety-related restrictions or limitations Contraindicated in patients with untreated narrow-angle glaucoma. Caution is advised due to the potential for clinically significant bleeding events when combined with certain other medications.

Safety Classifications (High-Level)

Category Description
Regulatory frequency framework used Frequency bands established in clinical trials (e.g., Very Common ge 1/10).
Regulatory basis US Food and Drug Administration and European Medicines Agency prescribing information.
Context-of-use safety notes (as defined in official documents) The label specifies that sudden discontinuation should be avoided. Regular blood pressure and heart rate monitoring is required during treatment.

Resulting Safety Structure

Regulatory safety summary:

  • The safety profile is dominated by Very Common and Common adverse reactions primarily affecting the gastrointestinal and nervous systems, such as nausea and headache.
  • The regulatory documentation explicitly warns of the potential for serious reactions, including Serotonin Syndrome and Hepatotoxicity, which are key considerations for the SNRI drug class.
  • Official safety constraints prohibit use in specific patient groups, notably those with severe renal or hepatic impairment, and in the presence of untreated narrow-angle glaucoma.

Connection to the Overall Safety Profile

The official safety information strictly defines the risk profile of milnacipran through structured classification, linking observed effects to frequency and specific physiological systems. This formal regulatory structure ensures that potential serious, though infrequent, adverse reactions are highlighted alongside the common, anticipated effects observed more frequently during the initial phases of exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents describe specific clinical manifestations associated with milnacipran overdose, requiring immediate medical attention. Documented overdose presentations may include changes in the level of consciousness, ranging from somnolence to coma, along with instances of seizures and a confusional state. Other signs include cardiovascular effects such as tachycardia (increased heart rate) and hypertension (elevated blood pressure), as well as general symptoms like nausea and vomiting.

Severe outcomes reported in association with overdose include cardio-respiratory arrest and fatal outcomes. There is also a risk for the development of Serotonin Syndrome. Immediate medical help must be sought if a victim has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Contacting a poison control center is also a mandated emergency action.

Management is strictly supportive and symptomatic as no specific antidote is known. Required procedures include securing an adequate airway, oxygenation, and ventilation, along with continuous monitoring of cardiac rhythm and vital signs. Gastrointestinal decontamination using gastric lavage and activated charcoal should be considered in symptomatic patients. Management must also account for the possibility of multiple drug involvement. The drug label notes that hyponatremia (low sodium), a risk factor for severe symptoms, is more common in elderly patients.

Therapeutic Uses of Savella

Milnacipran is commonly used in adult patients for the long-term management of the complex, long-lasting condition known as Fibromyalgia (FM). The medication is considered relevant for use in conditions where symptoms may intensify temporarily, and is used to address the characteristic symptomatic manifestations of this condition.

Therapeutic Scope and Benefits

The therapeutic scope focuses on providing support that helps ease the overall symptom burden for symptoms related to physical discomfort and systemic imbalance, including widespread musculoskeletal pain, persistent fatigue, and associated cognitive and sleep disturbances. It is applied across domains where additional symptomatic support is needed, typically during phases when symptoms become more noticeable.

“The medication is applied across domains where additional symptomatic support is needed to help with managing symptoms that create noticeable physiological strain.”

Quick Fact: Relief for Systemic Symptoms

Domain Symptom Types Patient Benefit
Pain Chronic, widespread discomfort, muscle tenderness Supports maintaining functional stability
Fatigue Persistent, severe low energy levels Contributes to easing the overall symptom load
Cognition Difficulty concentrating, mental clarity issues Helps maintain a sense of stability

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Savella

The official population-eligibility profile for milnacipran defines clear boundaries for its use, based strictly on regulatory labeling.

Category Official Regulatory Statement
Contraindicated Prohibited for patients with uncontrolled narrow-angle glaucoma or those using, or recently using (within 14 days), a Monoamine Oxidase Inhibitor (MAOI), including linezolid or intravenous methylene blue.
Approved Age Group Adults (age 18 and older) only. The medicine is not approved for use in pediatric patients.
Renal Function Restriction Not recommended for patients with end-stage renal disease. Use in severe renal impairment requires specific restricted conditions.
Hepatic Function Restriction Caution is advised in cases of severe hepatic impairment. Use should be avoided with chronic liver disease or substantial alcohol use.
Pregnancy/Lactation Caution is recommended during breastfeeding as the drug is excreted into human milk. Use during the third trimester of pregnancy may carry risks to the neonate.

The official guidelines impose strict eligibility constraints, primarily through absolute contraindications. Eligibility is strictly limited to the adult population, with explicit exclusion of pediatric patients. Regulatory documents also impose use restrictions on individuals with compromised organ function, such as severe renal impairment, and advise caution for patients with a history of seizures or other listed health issues.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of milnacipran primarily through pharmacodynamic effects rather than major metabolic (CYP) or transporter-mediated interactions, which are stated to be unlikely to be clinically significant. The most severe constraints are formal contraindications with certain drug classes.

Interaction Classifications (High-Level)

Classification Description
Interaction severity classification Contraindicated (MAOIs); Caution (Serotonergic agents, Hemostatic agents).
Timing-based interaction rules Mandatory separation periods when switching between milnacipran and an MAOI intended for psychiatric disorders.

Official Interaction Statements

  • Monoamine Oxidase Inhibitors (MAOIs): Co-administration with MAOIs, including psychiatric agents (e.g., phenelzine) and non-psychiatric agents (e.g., linezolid, intravenous methylene blue), is strictly contraindicated due to the potentially fatal risk of Serotonin Syndrome. At least 14 days must elapse after discontinuing an MAOI before starting milnacipran, and at least 5 days must elapse after stopping milnacipran before starting an MAOI.
  • Other Serotonergic Agents: Co-administration with other serotonergic medicines (e.g., Triptans, SSRIs, tramadol, St. John’s Wort) may increase the risk of Serotonin Syndrome.
  • Drugs that Interfere with Hemostasis: Concomitant use with agents such as NSAIDs, aspirin, or warfarin may increase the risk of bleeding events.
  • Catecholamines: Co-administration with epinephrine or norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia.
  • Alcohol/Chronic Liver Disease: The regulatory label advises to avoid concomitant use in patients with substantial alcohol use or chronic liver disease due to the documented risk of hepatotoxicity.

Mechanism of Action

Dual Inhibition of Serotonin and Norepinephrine Transporters

The core mechanism of milnacipran is the dual inhibition of the Serotonin Transporter ( SERT) and the Norepinephrine Transporter ( NET) in the central nervous system ( CNS). By blocking the reuptake of these two key neurotransmitters, the drug causes a sustained, functional increase in their concentrations in the spaces between neurons. Milnacipran is pharmacologically notable for maintaining a balanced potency ratio between its action on SERT and NET, which facilitates the functional augmentation of both monoamine systems.


Augmentation of Central Nociceptive Pathways

The resulting elevation of serotonin and norepinephrine centrally enhances the activity of the Descending Inhibitory Pain Pathways ( DIPP), which originate in the brainstem and project to the spinal dorsal horn. This systemic enhancement of the body's natural inhibitory systems leads to a cascade effect: the increased neurotransmitter availability directly inhibits the transmission of nociceptive signals at the level of the spinal cord. This action ultimately modulates the central nervous system's processing of stimuli, which leads to a systemic attenuation of afferent signaling.

Dosage and Administration Information

How Savella is Used: Official Administration Guidelines

Savella (milnacipran) is a prescription medicine administered via the oral route as an immediate-release, film-coated tablet. The use of the medication is defined by a structured, one-week titration schedule, which is designed to lead into a long-term maintenance phase. All administration instructions are established by regulatory documents and do not include individualized medical advice or safety information.


Labeled Dosing Schedule

Treatment initiation begins with a low dose that is gradually increased over seven days to reach the recommended consistent daily intake. This approach involves taking the medicine in divided doses twice per day after the initial day of use.

Administration Phase Daily Dose Administration Schedule
Day 1 12.5 mg Once daily
Days 2-3 25 mg 12.5 mg twice daily
Days 4-7 50 mg 25 mg twice daily
Maintenance (After Day 7) 100 mg 50 mg twice daily

The maximum recommended daily dose is 200 mg (100 mg twice daily). The medication may be taken with or without food; however, consuming it with food may aid in tolerability.


Rules for Specific Populations and Procedural Constraints

The established usage rules mandate specific procedural constraints. The medication is not approved for use in pediatric patients under the age of 18.

For patients with severe renal impairment (creatinine clearance 5-29 mL/min), the maintenance dosage must be reduced by 50% to 50 mg per day (25 mg twice daily). Use is not recommended for end-stage renal disease.

If a dose is missed, regulatory instructions advise the patient to skip the missed dose and resume the regular schedule; doses should not be doubled to compensate. Upon discontinuation after extended use, the dosage must be tapered gradually to minimize systemic impact.

Recent Clinical Evidence

Savella: Recent Clinical Evidence

The research supporting the use of Savella (milnacipran) primarily focuses on its role in the management of fibromyalgia in adults. Regulatory approval was based on evidence derived from large-scale, double-blind, placebo-controlled trials.


Clinical Efficacy Summary

Studies examined the effect of milnacipran using composite responder criteria, which required patients to demonstrate concurrent improvements in several core fibromyalgia symptoms. A significantly greater proportion of patients receiving milnacipran (100 mg/day or 200 mg/day) met these composite response criteria compared to patients receiving placebo.

  • Pain Reduction: In pivotal trials, milnacipran was associated with achieving moderate pain relief (at least a 30% reduction in pain intensity) in approximately 40% of participants, compared to approximately 30% with placebo. Reductions in pain scores were documented as early as one week in some participants.
  • Other Symptoms: Research also documented changes in secondary outcomes, including fatigue, physical function, and global patient assessment scores, when compared to placebo.

Safety and Tolerability Findings

Safety data were gathered across the clinical program. The agent was generally associated with an increase in common adverse events compared to placebo, although serious adverse events did not show a difference between groups.

The most frequently documented adverse events (occurring at a rate greater than 5% and exceeding the placebo rate) included:

  • Nausea
  • Headache
  • Constipation
  • Dizziness

Withdrawals from the studies due to adverse events were more common in the milnacipran groups, especially at the higher 200 mg/day dose. Milnacipran is not approved for use in pediatric patients.

Frequently Asked Questions (FAQ)

Common questions about Savella (FAQ)


Q: What happens if a dose of Savella is missed?

If a dose is missed, regulatory documents advise skipping the missed dose entirely. The patient should then resume the regular dosing schedule at the next scheduled time. It is advised not to take a double dose at one time to try and make up for a dose that was forgotten.


Q: Can Savella be taken with over-the-counter pain medications like ibuprofen?

Regulatory documents caution about a potentially increased risk of bleeding when Savella is used together with certain nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. Official information advises patients to be aware of this potential interaction.


Q: Does alcohol use affect the safety or effectiveness of Savella?

Official documentation advises caution regarding the use of alcoholic beverages while taking Savella. The medicine is specifically advised against for use in patients with substantial alcohol use or chronic liver disease, due to the risk of potential liver damage.


Q: How should Savella be stored?

The official product information specifies that Savella should be stored in its closed container at room temperature. It must be kept away from excessive heat, moisture, and direct light, and protected from freezing.


Q: Can Savella be crushed or split to take?

Savella is manufactured as an immediate-release, film-coated tablet. The official product information does not include instructions regarding crushing, splitting, or physically altering the tablets.


Q: What are the symptoms of an overdose of Savella?

Symptoms reported in regulatory contexts following acute overdose include confusion, extreme sleepiness, dizziness, and vomiting. Changes in heart rate and blood pressure, such as a fast heart rate and high blood pressure, were also reported.


Q: Is Savella an antidepressant or a pain reliever?

In the United States, Savella is officially approved only for the management of fibromyalgia, which is a chronic pain condition. It is chemically categorized as a selective serotonin and norepinephrine reuptake inhibitor (SNRI), a drug class that includes some medicines used to treat depression.


Q: Why is Savella prescribed for fibromyalgia and not other conditions?

In the U.S., Savella has received regulatory approval specifically for the management of fibromyalgia. It received regulatory approval based on clinical trial evidence supporting its use for this condition.


Q: How quickly do people typically notice a change after starting Savella?

Clinical trial evidence has not established a specific timeframe for patients to notice the full effect of the medicine. Official documentation indicates that, like similar treatments, it may take several weeks for the effects to become fully evident.


Q: Does Savella help with fatigue associated with fibromyalgia?

Clinical studies supporting the drug’s approval focused on key symptoms such as pain and changes in physical function. While fatigue is a symptom often associated with fibromyalgia, the drug’s approved indication relates to the overall management of the condition.


Q: What is the main difference between Savella and Cymbalta?

Both Savella (milnacipran) and Cymbalta (duloxetine) are classified as selective serotonin and norepinephrine reuptake inhibitors (SNRIs). However, their specific approved uses differ in the U.S. Savella is only approved for fibromyalgia, while Cymbalta has approval for fibromyalgia alongside other conditions.


Q: Can Savella cause weight gain or weight loss?

In clinical trials, changes in body weight were reported as adverse reactions. Official product information notes that decreased weight was a common occurrence, while increased weight was reported less frequently among patients.


Q: Is it common to feel worse when first starting Savella?

Many of the most common side effects, such as nausea, headache, and constipation, tend to be reported more often when treatment is first started. Official information describes a gradual dose increase procedure intended to help manage how the patient tolerates the initial phase of treatment.


Q: Can Savella affect sleep patterns?

Yes, official regulatory information reports that difficulty falling or staying asleep (insomnia) is one of the common side effects that was observed in clinical trials.


Q: Are there specific foods or drinks to avoid while taking Savella?

Savella may be taken with or without food according to official labeling. Beyond advising caution regarding substantial alcohol use, regulatory sources do not list specific dietary restrictions that must be followed.


Q: What if Savella doesn't seem to be working after a few weeks?

The drug is intended for the long-term management of fibromyalgia. The evidence for the approved use is based on clinical trials spanning several months, which suggests that the full effect of the medication may take time to become apparent.


Q: Is Savella known to cause sexual side effects?

Yes, sexual dysfunction was reported as an adverse reaction in clinical trials. This can include decreased libido (sex drive) and issues with ejaculation in male patients.


Q: Does Savella affect blood pressure or heart rate?

Official labeling states that the medication can lead to sustained increases in both heart rate and blood pressure, and these factors should be monitored during the course of treatment. Cases of significant blood pressure elevation have been reported.


Q: Is Savella considered a controlled substance?

No, according to regulatory classification in the U.S., Savella (milnacipran) is not designated as a controlled substance under the Controlled Substances Act.


Q: What is the risk of dependence or withdrawal with Savella?

Regulatory documents state that withdrawal symptoms have been reported following the sudden discontinuation of treatment. A gradual reduction in dosage is officially recommended when stopping the medicine to help minimize potential discontinuation symptoms.


Q: Can Savella be taken during pregnancy?

Regulatory information indicates that, based on data from animal studies, there is a potential for the drug to cause harm to the developing fetus. The official label advises that the medication should be used during pregnancy only if the potential benefit to the patient is believed to justify the potential risk to the fetus.


Q: Is Savella safe for older adults to use?

Official studies observed no overall differences in efficacy or safety between older and younger adults in clinical trials. However, the official label notes that greater sensitivity of some older individuals to the effects of the drug cannot be completely ruled out.


Q: Are there common reasons why a doctor might stop prescribing Savella?

Official information indicates that the medication may be discontinued due to specific safety concerns. These can include a sustained increase in heart rate or blood pressure, or the emergence of signs of liver damage (hepatotoxicity).


Q: Do studies support the long-term use of Savella?

The drug's approved indication for the management of fibromyalgia is based on clinical trials, including those of an extended duration, which support its use as a treatment intended for long-term administration.


Q: Does Savella cause 'brain fog' or difficulty concentrating?

Difficulty concentrating is reported in regulatory contexts. This symptom may occur in the context of hyponatremia (low sodium levels), which is an adverse reaction that can potentially develop during treatment.


Q: What is the chemical name for Savella?

The active ingredient in Savella is milnacipran hydrochloride. The official chemical name is (±)-cis-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride.


Q: Can Savella be used by people with kidney problems?

Official prescribing information indicates that the use of Savella is generally not recommended for patients who have end-stage kidney disease. For people with moderate or severe kidney impairment, a lower total daily dose is described in the official product information.


Q: Is there a generic version of Savella available?

The active ingredient in Savella is milnacipran. Generic versions of milnacipran hydrochloride tablets have received approval from the FDA for use in the U.S.


Q: How does Savella compare to Lyrica for fibromyalgia?

Savella (milnacipran) and Lyrica (pregabalin) are both approved by the FDA for the management of fibromyalgia. However, they belong to different classes of medication: Savella is an SNRI, and Lyrica is an anticonvulsant and GABA analog. They act on the body through different mechanisms.


Q: What is the typical age range of people prescribed Savella?

The medication is officially approved for use in adult patients, meaning those 18 years of age and older. The clinical trials supporting its use focused on the adult population, including older adults with fibromyalgia.


Q: Does Savella interact with supplements like St. John's Wort?

Official warnings state that Savella should not be taken concurrently with other agents that increase serotonin levels, which includes herbal supplements such as St. John's Wort. Taking them together may increase the risk of a serious condition called Serotonin Syndrome.


Q: Is it normal to have increased sweating while on Savella?

Yes, based on clinical trial data, increased sweating (hyperhidrosis) is reported as a very common side effect associated with taking this medication.


Q: Can people with a history of depression take Savella?

The drug carries a warning regarding the potential risk of suicidal thoughts and behaviors, particularly in young adults. Because depression itself is associated with an increased risk of suicide, patients taking Savella who have a history of depression require careful monitoring according to official guidance.


Q: Can Savella affect liver function tests?

Official information indicates that the drug has been associated with mild elevations of certain liver enzymes (ALT and AST) in clinical trials. In rare cases, more severe liver damage, known as fulminant hepatitis, has been reported.


Q: Is Savella a monotherapy or is it usually combined with other treatments?

Savella is approved for the management of fibromyalgia. Official documents do not mandate that it be used as a monotherapy. In clinical practice, the management of fibromyalgia often involves a comprehensive approach that includes both drug and non-drug therapies.


Q: Can Savella cause confusion or dizziness?

Yes, dizziness is reported as a common side effect in clinical trials. Confusion has also been reported as a potential symptom of hyponatremia (low sodium levels), which is an adverse reaction that may occur during treatment.


Q: Is Savella effective for men and women equally?

Clinical trials for the approved use of Savella included both male and female patients, and the drug is approved for the adult population as a whole. The official prescribing information does not generally provide separate, detailed data on efficacy broken down specifically by sex.


Q: What is the difference between an SNRI like Savella and an SSRI?

Savella is classified as a Selective Serotonin and Norepinephrine Reuptake Inhibitor (SNRI). It is believed to work by increasing the levels of both chemical messengers, serotonin and norepinephrine, in the central nervous system. Selective Serotonin Reuptake Inhibitors (SSRIs) primarily work by increasing the levels of only serotonin.


Q: Does Savella work immediately or does it need time to build up in the system?

While the drug is rapidly absorbed into the body, the therapeutic action that results in the clinical effect for fibromyalgia may take time. The official dose instructions involve a gradual increase over several days, suggesting the full effect is not immediate.


Q: Are there any warnings about driving or operating machinery while taking Savella?

The official Patient Medication Guide cautions that this medication may cause drowsiness or affect an individual's judgment, thinking, and movements. Official guidance cautions against driving or operating hazardous machinery until patients are aware of how the medication affects them.


Q: What is the half-life of Savella in the body?

The mean elimination half-life of the active ingredient, milnacipran, in the body is approximately 8 hours. This measure describes the time it takes for half of the drug to be eliminated from the bloodstream.


Q: Does Savella cause insomnia or vivid dreams?

Difficulty sleeping (insomnia) is reported as a common side effect in the official product information. While insomnia is common, vivid dreams are not explicitly listed in the very common or common side effect categories.


Q: Can Savella make anxiety worse?

The official Patient Medication Guide advises that new or worsening symptoms of anxiety and panic attacks should be monitored, especially when a patient first starts the medication or when the dosage is increased.


Q: What is the main function of norepinephrine reuptake inhibition in Savella?

Savella is an SNRI that prevents the reabsorption (reuptake) of norepinephrine, which is a chemical messenger in the central nervous system. This action is thought to contribute to the drug's overall mechanism and its effect in managing fibromyalgia.


Q: Are there specific patient groups that should use caution with Savella?

Official warnings and precautions exist for several patient groups. These include people with a history of seizures, uncontrolled narrow-angle glaucoma, pre-existing high blood pressure or certain heart conditions, and those with a history of substantial alcohol use.

How should Savella be stored and disposed of?

How to Store and Dispose of Savella (Milnacipran HCl)

Savella tablets must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F). Brief temperature excursions are allowed between 15°C and 30°C. The medication requires protection from environmental factors, meaning it must be stored away from heat, moisture, and direct light.

Storage and Handling Requirements

Requirement Official Instruction
Temperature Do not freeze the product.
Container Keep in a tightly closed container to maintain product integrity.
Safety Must be kept out of the reach of children.

For disposal, unused or outdated medicine should not be kept. Regulatory instructions require consulting a healthcare professional or pharmacist for guidance on the proper method for discarding the remainder of the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Savella found in:

A-Z Index: